טוען...
Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With (131)I-Metaiodobenzylguanidine (MIBG)
BACKGROUND. (131)I-metaiodobenzylguanidine ((131)I-MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor-specific uptake, the treatment with (131)I-MIBG results in whole-body radiation exposure. Our aim was to correlate whole-body radiation dose (WBD) from (131)I...
שמור ב:
| הוצא לאור ב: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523914/ https://ncbi.nlm.nih.gov/pubmed/26506090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25816 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|